A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Distinct / DIV-SCLC-301
NCT03098030
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
Phase II |
Nicola Raby
514-934-1934 poste 34095
|
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
ADRIATIC
NCT03703297
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Corneille Bashagaluke
514-934-1934 poste 34907
|
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment
20200491
NCT05060016
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Marie-Pierre Brochu
418-525-4444 poste 15768
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Josée Allard
418-525-4444 poste 16730
|
Evaluation of Deployment Capability and Accuracy of an Outside the Scope (OTS), Detachable Catheter System for Ablation of Peripheral Lung Lesions: An Ex-Vivo Human Lung Model Study
CT0099
NCT04722432
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Adeline Jouquan
514-890-8000 poste 26214
|
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Recruiting
|
CISSS DE CHAUDIERE-APPALACHES
HOTEL-DIEU DE LEVIS
|
|
Pierre Bédard
418-835-7121
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Patricia Roy
819-346-1110 poste 14082
|
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy
MK-3475-B98/KEYNOTE-B98
NCT04938817
Recruiting
|
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY
|
|
Rachelle Dumas
514-345-3511 poste 3378
|
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer
BRC.8 / SWOG S1827 (MAVERICK)
NCT04155034
Recruiting
|
CIUSSS DE LA MAURICIE-ET-DU-CENTRE-DU-QUEBEC
CHAUR
|
|
Marie-Ève Caron
819-697-3333 poste 63238
|
Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
EMERGE 402 (JZP712-402)
NCT04894591
Recruiting
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Pascale Duchesne
418-541-1000 poste 2840
|
Groupe d'étude en oncologie du Québec